Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · IEX Real-Time Price · USD
0.34 (3.07%)
May 20, 2022 4:00 PM EDT - Market closed

Company Description

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.

The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.

It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.

Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc.
CountryUnited States
IPO DateMar 26, 2021
SectorHealth Care

Contact Details

6005 Hidden Valley Road
Carlsbad, CA 92011
United States
Phone858 293 4900

Stock Details

Ticker SymbolDSGN
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$20.00
CIK Code1807120

Key Executives

Dr. João Siffert M.D.President, Chief Executive Officer and Director
Dr. Sean Jeffries Ph.D.Chief Operating Officer
Dr. Aseem Z. Ansari Ph.D.Co-Founder and Scientific Advisor
Julie D. Burgess CPAChief Accounting Officer
Dr. Elizabeth Gordon Ph.D.Senior Vice President of Regulatory Affairs
Dr. Jae B. Kim FACC, M.D.Chief Medical Officer
Dawn GiangiulioController

Latest SEC Filings

May 10, 2022EFFECTNotice of Effectiveness
May 9, 202210-QQuarterly report [Sections 13 or 15(d)]
May 9, 20228-KCurrent report
Apr 27, 2022S-3Registration statement under Securities Act of 1933
Apr 27, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 27, 2022DEF 14AOther definitive proxy statements
Mar 31, 2022SC 13DGeneral statement of acquisition of beneficial ownership
Mar 22, 20224Statement of changes in beneficial ownership of securities
Mar 22, 20224Statement of changes in beneficial ownership of securities
Mar 22, 20228-KCurrent report
View All SEC Filings